Investment Thesis
Biomea Fusion is a pre-revenue biotech firm with catastrophic cash burn ($11.7M quarterly operating loss) against minimal revenue ($430K, declining 67% YoY), leaving no margin for safety in operations. Despite adequate cash reserves ($44.7M), the company's fundamentals show value destruction at all levels—negative ROE/ROA, zero commercial traction, and a burn rate that exhausts runway within 12-15 months without additional capital or revenue inflection.
Strengths
- Debt-free balance sheet with zero leverage (Debt/Equity 0.00x)
- Strong liquidity position (Current Ratio 4.98x) for near-term obligations
- Adequate cash reserves ($44.7M) providing operational runway
Risks
- Acute cash burn of $11.7M per quarter with minimal revenue—reserves deplete in 12-15 months
- Revenue collapsed 67% YoY to $430K—no evidence of commercial product viability
- Extreme negative margins (Operating: -2971%, Net: -2887%) indicate unsustainable development-stage losses
- No visible path to profitability or commercial traction in SEC filings
Key Metrics to Watch
- Quarterly revenue growth (reversed negative 67% decline)
- Operating cash burn rate (absolute dollars, trajectory toward breakeven)
- Cash runway (months until depletion at current burn rate)
- Clinical trial advancement or FDA milestone achievements
Financial Metrics
Revenue
430.0K
Net Income
-12.4M
EPS (Diluted)
$-0.17
Free Cash Flow
-11.7M
Total Assets
46.4M
Cash
44.7M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-2,970.7%
Net Margin
-2,887.2%
ROE
-66.3%
ROA
-26.8%
FCF Margin
-2,713.7%
Balance Sheet & Liquidity
Current Ratio
4.98x
Quick Ratio
4.98x
Debt/Equity
0.00x
Debt/Assets
59.6%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-12T06:53:31.917108 |
Data as of: 2026-03-31 |
Powered by Claude AI